Hypertension Clinical Trials

Find Hypertension Clinical Trials Near You

Salt Intake and Blood Pressure Control in Adults With Essential Hypertension

Status: Recruiting
Location: See location...
Intervention Type: Behavioral
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The goal of this study is to explore the barriers and facilitators to adopting a reduced dietary salt and increased potassium intake among adults with essential hypertension in Singapore, and to evaluate the feasibility and preliminary effectiveness of a newly developed educational tool-Decreased Salt High Potassium (DSHP) Diet Tool-in reducing dietary sodium intake and increasing potassium intake. This three-part study will involve adults aged 21 years and above, with a self-reported diagnosis of hypertension for at least six months and/or currently taking antihypertensive medication. Participants will be recruited from two SingHealth Polyclinics (Punggol Polyclinic and Pasir Ris Polyclinic). Healthcare providers (HCPs) working at these clinics who have experience in managing patients with hypertension and in educating patients on reducing dietary sodium intake will also be recruited. The main questions this study aims to answer are: * What are the perceived barriers and facilitators for patients with hypertension to reduce dietary sodium and increase potassium intake? * What are the perceived barriers and facilitators experienced by healthcare providers in educating patients about sodium reduction and potassium intake? * Is the DSHP Diet Tool feasible and effective in reducing dietary sodium intake and increasing potassium intake among patients with hypertension? Participants in the intervention group will be provided DSHP Diet Tool and Decreased Salt High Potassium patient information leaflet (DSHP PIL). Participants in the control group will receive standard care and a patient information leaflet (DSHP PIL). Researchers will compare participants in the intervention group to the control group to determine whether the DSHP tool is effective in reducing dietary sodium and increasing potassium intake in patients with hypertension.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 21
Healthy Volunteers: f
View:

• Participants who are 21 years old and above.

• Participants who self-reports to have hypertension for at least six months and/ or taking at least one type of antihypertensive medication daily for at least six months

• Able to read English

• HCPs who had prior experience in advising patients on dietary salt reduction

• HCPs who self-reported to have ever treated patients with hypertension

Locations
Other Locations
Singapore
Jingfeng Sun
RECRUITING
Singapore
Contact Information
Primary
SUN JINGFENG, Masters in Medicine(Fam Med)
jingfengsun88@gmail.com
+6591390121
Time Frame
Start Date: 2026-04-01
Estimated Completion Date: 2030-07-31
Participants
Target number of participants: 190
Treatments
Experimental: DSHP Diet Tool and DSHP Patient information leaflet
Participants in this arm will receive standard hypertension care along with access to the Decreased Salt High Potassium (DSHP) Diet Tool for 24 weeks and DSHP Patient information leaflet. The DSHP Tool is a patient-centered educational resource developed to support sodium reduction and increase potassium intake through practical strategies, goal setting, and food guidance. Participants will also receive the DSHP Patient Information Leaflet (PIL). Patients will be guided on how to use the tool by a study coordinator. Clinical and dietary assessments will be conducted at baseline and at the end of the intervention.
No_intervention: Standard Care + DSHP Patient Information Leaflet
Participants in this arm will receive standard hypertension care as provided at SingHealth Polyclinics, along with the DSHP Patient Information Leaflet (PIL). The PIL provides written guidance on reducing sodium and increasing potassium intake. No access to the DSHP Tool will be provided in this arm. Participants will undergo the same clinical and dietary assessments as the intervention group at baseline and after 24 weeks.
Related Therapeutic Areas
Sponsors
Leads: Sun Jingfeng

This content was sourced from clinicaltrials.gov